Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Sovateltide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sun Pharma To Invest Up To $15M In Pharmazz
    Sun Pharma To Invest Up To $15M In Pharmazz

    21 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/21/2933391/0/en/Pharmazz-Inc-and-Sun-Pharma-entered-into-an-agreement-under-which-Sun-Pharma-will-invest-up-to-15-Million-in-Pharmazz-Inc.html

    GLOBENEWSWIRE
    21 Aug 2024
    Share Share
    A Special Protocol Assessment Agreement Reached with FDA for Ph 3 of Sovateltide
    A Special Protocol Assessment Agreement Reached with FDA for Ph 3 of Sovateltide

    02 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/02/2752648/0/en/A-Special-Protocol-Assessment-Agreement-Reached-with-the-U-S-Food-and-Drug-Administration-for-Phase-3-clinical-trial-of-Sovateltide-for-the-treatment-of-acute-cerebral-ischemic-str.html

    GLOBENEWSWIRE
    02 Oct 2023
    Share Share
    Pharmazz Announces US FDA Clearance for a PhIII Clinical Trial of Sovateltide
    Pharmazz Announces US FDA Clearance for a PhIII Clinical Trial of Sovateltide

    13 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pharmazz-inc-announces-us-fda-clearance-for-a-phase-iii-clinical-trial-of-sovateltide-pmz-1620-in-acute-cerebral-ischemic-stroke-patients-301744465.html

    PR NEWSWIRE
    13 Feb 2023
    Share Share
    Clinical PIII Trial Results Demonstrating Sovateltide's Efficacy
    Clinical PIII Trial Results Demonstrating Sovateltide's Efficacy

    10 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/clinical-phase-iii-trial-results-demonstrating-sovateltides-efficacy-to-treat-acute-cerebral-ischemic-stroke-presented-at-the-international-stroke-conference-2023-301741886.html

    PR NEWSWIRE
    10 Feb 2023
    Share Share
    Pharmazz Presents Results of PIII Trial Demonstrating Sovateltide’s Efficacy
    Pharmazz Presents Results of PIII Trial Demonstrating Sovateltide’s Efficacy

    31 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/31/2544513/0/en/Pharmazz-Inc-Presents-Positive-Results-of-Phase-III-Clinical-Trial-Demonstrating-Sovateltide-s-Efficacy-as-a-Treatment-for-Acute-Cerebral-Ischemic-Stroke.html

    GLOBENEWSWIRE
    31 Oct 2022
    Share Share
    Pharmazz announces Indian (CDSCO) Clearance of IND to a Phase 2 sovateltide
    Pharmazz announces Indian (CDSCO) Clearance of IND to a Phase 2 sovateltide

    29 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/29/2505915/0/en/Pharmazz-Inc-announces-Indian-Central-Drugs-Standard-Control-Organization-CDSCO-Clearance-of-IND-to-conduct-a-Phase-II-clinical-trial-of-sovateltide-PMZ-1620-in-hypoxic-ischemic-en.html

    GLOBENEWSWIRE
    29 Aug 2022
    Share Share